Market Place
Sourcing Support
Crinetics Submits NDA For Paltusotine For Treatment Of Acromegaly
26 Sep 2024 //
GLOBENEWSWIRE
Crinetics Positions Paltusotine As Potential Acromegaly First Choice
03 Jun 2024 //
GLOBENEWSWIRE
Crinetics At ENDO On Atumelnant, Paltusotine Programs
08 May 2024 //
GLOBENEWSWIRE
Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission
20 Mar 2024 //
BIOSPACE
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine
12 Mar 2024 //
GLOBENEWSWIRE
Crinetics Announces Positive Findings from Open-Label Phase 2 of Paltusotine
18 Dec 2023 //
GLOBENEWSWIRE
Crinetics’ Oral Paltusotine Achieved The Primary And All Secondary Endpoints
10 Sep 2023 //
PRESS RELEASE
New Data Demonstrating Stable Biochemical and Symptom Levels Oral Paltusotine
21 Jun 2023 //
GLOBENEWSWIRE
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine
13 Oct 2022 //
GLOBENEWSWIRE
Crinetics Pharma, Sanwa Kagaku Kenkyusho Enter Partnership
28 Feb 2022 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.